{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:36:39Z","timestamp":1790026599734,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.omtn.2024.102334","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:10:06Z","timestamp":1725927006000},"page":"102334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Novel readthrough agent suppresses nonsense mutations and restores functional type VII collagen and laminin 332 in epidermolysis bullosa"],"prefix":"10.1016","volume":"35","author":[{"given":"Brandon","family":"Levian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingping","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liat","family":"Bainvoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasu","family":"Badarinarayana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheil","family":"Aghamohammadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6809-147X","authenticated-orcid":false,"given":"Mei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2024.102334_bib1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.abd.2020.05.001","article-title":"Inherited epidermolysis bullosa: update on the clinical and genetic aspects","volume":"95","author":"Mariath","year":"2020","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.omtn.2024.102334_bib2","doi-asserted-by":"crossref","first-page":"39S","DOI":"10.1038\/jid.1994.8","article-title":"Molecular basis of the dystrophic and junctional forms of epidermolysis bullosa: mutations in the type VII collagen and kalinin (laminin 5) genes","volume":"103","author":"Uitto","year":"1994","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.omtn.2024.102334_bib3","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.ajpath.2017.03.003","article-title":"Pathomechanisms of Altered Wound Healing in Recessive Dystrophic Epidermolysis Bullosa","volume":"187","author":"Cianfarani","year":"2017","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtn.2024.102334_bib4","series-title":"GeneReviews(\u00ae)","article-title":"Dystrophic Epidermolysis Bullosa","author":"Pfendner","year":"1993"},{"key":"10.1016\/j.omtn.2024.102334_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2147\/CCID.S54681","article-title":"Dystrophic epidermolysis bullosa: a review","volume":"8","author":"Shinkuma","year":"2015","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"10.1016\/j.omtn.2024.102334_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5582\/irdr.2017.01005","article-title":"Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa","volume":"6","author":"Rashidghamat","year":"2017","journal-title":"Intractable Rare Dis. Res."},{"key":"10.1016\/j.omtn.2024.102334_bib7","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","article-title":"Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa","volume":"387","author":"Guide","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2024.102334_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4161\/cam.22418","article-title":"Laminin 332 in junctional epidermolysis bullosa","volume":"7","author":"Kiritsi","year":"2013","journal-title":"Cell Adhes. Migrat."},{"key":"10.1016\/j.omtn.2024.102334_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00439-004-1210-y","article-title":"Novel and recurrent mutations in the laminin-5 genes causing lethal junctional epidermolysis bullosa: molecular basis and clinical course of Herlitz disease","volume":"116","author":"M\u00fchle","year":"2005","journal-title":"Hum. Genet."},{"key":"10.1016\/j.omtn.2024.102334_bib10","doi-asserted-by":"crossref","first-page":"E6536","DOI":"10.1073\/pnas.1803154115","article-title":"Gentamicin induces LAMB3 nonsense mutation readthrough and restores functional laminin 332 in junctional epidermolysis bullosa","volume":"115","author":"Lincoln","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2024.102334_bib11","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jid.2016.06.609","article-title":"Genotype, Clinical Course, and Therapeutic Decision Making in 76 Infants with Severe Generalized Junctional Epidermolysis Bullosa","volume":"136","author":"Hammersen","year":"2016","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.omtn.2024.102334_bib12","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/sj.jid.5701197","article-title":"Protein therapeutics for junctional epidermolysis bullosa: incorporation of recombinant beta3 chain into laminin 332 in beta3-\/- keratinocytes in\u00a0vitro","volume":"128","author":"Igoucheva","year":"2008","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.omtn.2024.102334_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2302\/kjm.2014-0013-RE","article-title":"Advances in Gene\/Cell Therapy in Epidermolysis Bullosa","volume":"64","author":"Murauer","year":"2015","journal-title":"Keio J. Med."},{"key":"10.1016\/j.omtn.2024.102334_bib14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature24487","article-title":"Regeneration of the entire human epidermis using transgenic stem cells","volume":"551","author":"Hirsch","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2024.102334_bib15","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/nm1504","article-title":"Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells","volume":"12","author":"Mavilio","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2024.102334_bib16","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jpeds.2007.06.039","article-title":"Cause-specific risks of childhood death in inherited epidermolysis bullosa","volume":"152","author":"Fine","year":"2008","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.omtn.2024.102334_bib17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/jmg.2005.039685","article-title":"Epidermolysis bullosa. I. Molecular genetics of the junctional and hemidesmosomal variants","volume":"43","author":"Varki","year":"2006","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.omtn.2024.102334_bib18","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/hmg\/8.10.1893","article-title":"Nonsense-mediated mRNA decay in health and disease","volume":"8","author":"Frischmeyer","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2024.102334_bib19","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/mt.2014.140","article-title":"Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa","volume":"22","author":"Cogan","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2024.102334_bib20","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.ymthe.2020.03.006","article-title":"Gentamicin Induces Laminin 332 and Improves Wound Healing in Junctional Epidermolysis Bullosa Patients with Nonsense Mutations","volume":"28","author":"Kwong","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2024.102334_bib21","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/jamadermatol.2021.5992","article-title":"Molecular and Clinical Outcomes After Intravenous Gentamicin Treatment for Patients With Junctional Epidermolysis Bullosa Caused by Nonsense Variants","volume":"158","author":"Mosallaei","year":"2022","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.omtn.2024.102334_bib22","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1172\/JCI92707","article-title":"Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients","volume":"127","author":"Woodley","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtn.2024.102334_bib23","first-page":"27","article-title":"Aminoglycoside nephrotoxicity","volume":"17","author":"Swan","year":"1997","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.omtn.2024.102334_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000013861","article-title":"Aminoglycoside antibiotics","volume":"5","author":"Forge","year":"2000","journal-title":"Audiol. Neurootol."},{"key":"10.1016\/j.omtn.2024.102334_bib25","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1080\/13543784.2020.1828862","article-title":"ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease","volume":"29","author":"Kerem","year":"2020","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.omtn.2024.102334_bib26","doi-asserted-by":"crossref","first-page":"10630","DOI":"10.1021\/jm3012992","article-title":"Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations","volume":"55","author":"Kandasamy","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.omtn.2024.102334_bib27","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/jcph.1807","article-title":"Phase 1 Renal Impairment Trial Results Supports Targeted Individualized Dosing of ELX-02 in Patients With Nephropathic Cystinosis","volume":"61","author":"Haverty","year":"2021","journal-title":"J.\u00a0Clin. Pharmacol."},{"key":"10.1016\/j.omtn.2024.102334_bib28","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/cpdd.647","article-title":"Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX-02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers","volume":"8","author":"Leubitz","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.omtn.2024.102334_bib29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/cpdd.914","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects","volume":"10","author":"Leubitz","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.omtn.2024.102334_bib30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/jpet.120.265595","article-title":"ELX-02 Generates Protein via Premature Stop Codon Read-Through without Inducing Native Stop Codon Read-Through Proteins","volume":"374","author":"Crawford","year":"2020","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.omtn.2024.102334_bib31","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jcf.2021.01.009","article-title":"Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids","volume":"20","author":"Crawford","year":"2021","journal-title":"J.\u00a0Cyst. Fibros."},{"key":"10.1016\/j.omtn.2024.102334_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223954","article-title":"The novel aminoglycoside, ELX-02, permits CTNSW138X translational read-through and restores lysosomal cystine efflux in cystinosis","volume":"14","author":"Brasell","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2024.102334_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/biom13060988","article-title":"Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development","volume":"13","author":"Li","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.omtn.2024.102334_bib34","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.tig.2008.08.010","article-title":"Introducing sense into nonsense in treatments of human genetic diseases","volume":"24","author":"Linde","year":"2008","journal-title":"Trends Genet."},{"key":"10.1016\/j.omtn.2024.102334_bib35","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.molmed.2012.09.008","article-title":"Sense from nonsense: therapies for premature stop codon diseases","volume":"18","author":"Bidou","year":"2012","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.omtn.2024.102334_bib36","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/ng1041","article-title":"Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa","volume":"32","author":"Chen","year":"2002","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2024.102334_bib37","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/1523-1747.ep12491525","article-title":"Junctional epidermolysis bullosa keratinocytes in culture display adhesive, structural, and functional abnormalities","volume":"97","author":"Krueger","year":"1991","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.omtn.2024.102334_bib38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.clpt.6100012","article-title":"Aminoglycoside-induced translational read-through in disease: overcoming nonsense mutations by pharmacogenetic therapy","volume":"81","author":"Zingman","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.omtn.2024.102334_bib39","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00109-001-0317-z","article-title":"Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system","volume":"80","author":"Keeling","year":"2002","journal-title":"J.\u00a0Mol. Med."},{"key":"10.1016\/j.omtn.2024.102334_bib40","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1172\/JCI34292","article-title":"A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy","volume":"118","author":"Fritsch","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtn.2024.102334_bib41","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1365-4632.2006.02774.x","article-title":"Compound heterozygosity in sibling patients with recessive dystrophic epidermolysis bullosa associated with a mild phenotype","volume":"45","author":"Shibusawa","year":"2006","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.omtn.2024.102334_bib42","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/pde.13083","article-title":"Compound Heterozygosity of Dominant and Recessive COL7A Alleles in a Severely Affected Patient with a Family History of Dystrophic Epidermolysis Bullosa: Clinical Findings, Genetic Testing, and Treatment Implications","volume":"34","author":"Watson","year":"2017","journal-title":"Pediatr. Dermatol."},{"key":"10.1016\/j.omtn.2024.102334_bib43","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/1523-1747.ep12265460","article-title":"Evaluation of anchoring fibrils and other components of the dermal-epidermal junction in dystrophic epidermolysis bullosa by a quantitative ultrastructural technique","volume":"84","author":"Tidman","year":"1985","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.omtn.2024.102334_bib44","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1046\/j.1523-1747.2003.12571.x","article-title":"Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone","volume":"121","author":"Woodley","year":"2003","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.omtn.2024.102334_bib45","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126243","article-title":"Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa","volume":"4","author":"Lwin","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2024.102334_bib46","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/jmg.2011.089615","article-title":"Efficiency of translation termination in humans is highly dependent upon nucleotides in the neighbourhood of a (premature) termination codon","volume":"48","author":"Pacho","year":"2011","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.omtn.2024.102334_bib47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jmg.2006.045302","article-title":"Epidermolysis bullosa. II. Type VII collagen mutations and phenotype-genotype correlations in the dystrophic subtypes","volume":"44","author":"Varki","year":"2007","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.omtn.2024.102334_bib48","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2147\/TCRM.S386923","article-title":"Innovations in the Treatment of Dystrophic Epidermolysis Bullosa (DEB): Current Landscape and Prospects","volume":"19","author":"Hou","year":"2023","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.omtn.2024.102334_bib49","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/BF02634257","article-title":"A method for the isolation and serial propagation of keratinocytes, endothelial cells, and fibroblasts from a single punch biopsy of human skin","volume":"31","author":"Normand","year":"1995","journal-title":"In\u00a0Vitro Cell. Dev. Biol. Anim."},{"key":"10.1016\/j.omtn.2024.102334_bib50","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/jcp.1041360118","article-title":"Laminin inhibits human keratinocyte migration","volume":"136","author":"Woodley","year":"1988","journal-title":"J.\u00a0Cell. Physiol."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216225312400221X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216225312400221X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T17:13:54Z","timestamp":1764177234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S216225312400221X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S216225312400221X"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2024.102334","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel readthrough agent suppresses nonsense mutations and restores functional type VII collagen and laminin 332 in epidermolysis bullosa","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2024.102334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102334"}}